Basic information Description Pharmacokinetics Uses Adverse Drug Reactions Controversy Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Hormones and the Endocrine System >  Prostaglandin drugs >  Misoprostol

Misoprostol

Basic information Description Pharmacokinetics Uses Adverse Drug Reactions Controversy Safety Supplier Related

Misoprostol Basic information

Product Name:
Misoprostol
Synonyms:
  • DL-MISOPROSTOL
  • Misoprostol API
  • Misogon
  • Misoprostil
  • Misoprostol, 1% in cellulose
  • SC 2933
  • Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11a,13E)- (9CI)
  • (11α,13E)-1l,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester
CAS:
59122-46-2
MF:
C22H38O5
MW:
382.54
EINECS:
664-288-5
Product Categories:
  • Active Pharmaceutical Ingredients
  • Prostaglandin
  • Fatty Acid Derivatives & Lipids
  • Glycerols
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Prostaglandins
  • Prostanoid receptor and related
  • API
  • Inhibitors
Mol File:
59122-46-2.mol
More
Less

Misoprostol Chemical Properties

Melting point:
261-263°C
Boiling point:
429.67°C (rough estimate)
Density 
1.0323 (rough estimate)
refractive index 
1.6120 (estimate)
storage temp. 
Sealed in dry,Store in freezer, under -20°C
solubility 
Practically insoluble in water, soluble in ethanol (96 per cent), sparingly soluble in acetonitrile.
pka
13.92±0.60(Predicted)
form 
neat
CAS DataBase Reference
59122-46-2(CAS DataBase Reference)
EPA Substance Registry System
Misoprostol (59122-46-2)
More
Less

Safety Information

Hazard Codes 
T
Risk Statements 
45-60-61-25-36/37/38
Safety Statements 
53-22-36/37/39-45
RIDADR 
UN 2810 6.1/PG 3
WGK Germany 
2
RTECS 
UK8390000
HS Code 
2937500000
Hazardous Substances Data
59122-46-2(Hazardous Substances Data)
Toxicity
LD50 in rats, mice (mg/kg): 40-62, 70-160 i.p.; 81-100, 27-138 orally (Kotsonis)
More
Less

Misoprostol Usage And Synthesis

Description

Misoprostol is a synthetic prostaglandin E1 analog that is commonly used for medical abortion, management of miscarriage, cervical priming, management of postpartum hemorrhage, and induction of labor. Because of misoprostol’s wide use in reproductive health, the drug is in the World Health Organization (WHO) Model List of Essential Medicines.

Pharmacokinetics

Routes for administering misoprostol include orally, sublingually, vaginally, rectally, or buccally. Pharmacokinetics studies carried out to compare vagina and oral administration have revealed that vaginal misoprostol is linked to slower clearance, lower peak plasma levels, and slower absorption, similar to an extended release preparation. Conversely, vaginal misoprostol is associated with more significant effects on the uterus and cervix due to the higher overall exposure to the drug.
Administration through the rectum revealed a similar pattern to vaginal administration; however, it has lower AUC and lower maximum peak concentration. The sublingual route has higher peak levels and more rapid absorption as compared to oral or vaginal administration.

Uses

Inducing Labor
Misoprostol is an effective and safe way of inducing labor although the Food and Drug Administration (FDA) has not yet approved it for use in pregnancy. However, the European Union (EU) approved its use after a study that was done between 2002 and 2012. It acts by causing uterine ripening and constrictions of the cervix.
Abortion
Misoprostol is normally used in combination with other drugs, such as methotrexate or mifepristone for medical abortion. It works by softening the cervix, causing it to open. Also, it makes the uterine muscles contract, thus inducing labor to expel the fetus. Misoprostol is a similar to prostaglandin which as a hormone that can cause a stronger reaction from the uterus. Most of the time, the drug is given in a clinic or hospital birthing centers.
Misoprostol can be best administered when one has passed 12 or more weeks of pregnancy to avoid possible severe complications. It can also be administered if there is a possibility of ectopic pregnancy or if one has an intrauterine device (IUD).
Misoprostol can be used either vaginally or orally if the pregnancy is still in the first trimester. The pregnant woman is advised to use 12 tablets of 200 grams and should put four tablets into the vagina or under the tongue and let it dissolve for 30 minutes. The woman is further advised to wait for 3 hours and repeat with four more pills in the vagina or under the tongue for 30 minutes.
The drug is more effective when inserted into the vagina; however, doctors usually administer it orally due to the possibility of infection when used vaginally. When used together with mifepristone, misoprostol is effective in approximately 95% of early pregnancies.
Postpartum Hemorrhage
Misoprostol is normally used both as treatment and prevention of postpartum hemorrhage secondary to its uterotonic properties. Studies have revealed that orally administered misoprostol is less effective as compared to oxytocin, but it still plays a vital role in treating postpartum hemorrhage when other agents fail or are not available.
Prevention of Ulcer
Misoprostol is commonly used for the treatment and prevention of NSAID-induced gastric and duodenal ulcers due to its analgesic and anti-inflammatory properties. It acts by inhibiting gastric acid inhibition of adenylate cyclase by G-protein coupled receptor that leads to decreased proton pump activity and decreased intracellular cyclic AMP levels at the apical surface of the parietal cell.
Failed Miscarriage
Misoprostol is used in treating a mother in case of fetal death that can result in miscarriage. It is also used in the termination of pregnancy for fetal anomalies. Initially, a low dose is administered and doubled for the extra doses until delivery.

Adverse Drug Reactions

The general adverse reactions experienced include contractions, abdominal pain, and GI intolerance and diarrhea. Many clinical studies revealed that about 13% of patients experienced diarrhea in the initial stages of therapy.
The most often reported side effects of orally taking the drug for the prevention and treatment of gastric ulcers include nausea, abdominal pain, headache, flatulence, dyspepsia, constipation, nausea, and constipation. Many patients experience fever when given multiple doses every 4 to 6 hours.
Women with wanted pregnancies are not supposed to take misoprostol to reduce the risk of increased uterine contractions and tone due to NSAID-induced gastric ulcers. This may cause complete or partial abortions or may lead to pregnancies with linked to congenital disabilities.
The drug may cause uterine hyperstimulation, which can affect the blood supply to the uterus negatively, thus increasing the chances of developing complications such as rupture of the womb.

Controversy

There have been numerous controversies regarding the use of misoprostol for induction of labor due to various reasons. The use of misoprostol and mifepristone for medical abortion has the potential of improving access to abortion services; therefore, political opponents of abortion may view the drugs as a target and a threat. It is noteworthy that in 2000, the FDA approved the use of mifepristone and misoprostol in conjunction with misoprostol for the termination of early pregnancy, yet misoprostol was not approved for the same purpose.

Description

Misoprostol is an orally-active PGEl analog useful in the treatment of gastric and duodenal ulcers. As with other agents of this type, misoprostol may prove useful as a gastric cytoprotective when administered concurrently with irritating drugs such as nonsteroidal antiinflammatories.

Chemical Properties

White Solid

Originator

Searle (USA)

Uses

antiulcerative;prostaglandin E1 analog that inhibits gastric acid secretion

Uses

A cytoprotective prostaglandin PGE1 analogue

Indications

Misoprostol (Cytotec), which is an analogue of prostaglandin E1, has been approved for use in the prevention of nonsteroidal antiinflammatory drug–induced ulceration. It also is approved in other countries for the treatment of peptic ulcer disease.

Manufacturing Process

1 method of synthesis
To a 1000 ml dried flask under a nitrogen atmosphere was added 74.6 g of(E)-trimethyl-[[1-methyl-1-[3-(tributylstannyl)-2-propenyl]pentyl]oxy]silane,125 ml anhydrous THF and 24.2 g of copper (I) iodide. The mixture wasstirred at room temperature for 30 minutes and then it was cooled to -25 to -30°C. 98.8 ml of methyllithium (2.86 M) in DEM was added dropwise and theresultant solution was stirred at -15°C for 2 hours. Then the reaction mixturewas cooled to -78°C and 25 g of methyl-5-oxo-3-[(triethylsilyl)oxy]-1-cyclopentene-1-heptanoate in 100 ml of THF was added rapidly. After stirringthe mixture for 5 min at -78°C, it was quenched into a mixture of 750 ml ofaqueous ammonium chloride solution and 200 ml of ammonium hydroxide.The resulting mixture was warmed to room temperature and stirred until adeep blue aqueous layer was obtained. Ethyl acetate (250 ml) was used forextraction. Then the combined organic layers were washed with brine andsubsequently dried over magnesium sulfate. After a filtration andconcentration under reduced pressure, an oil (105 g) was obtained. This oilcontaining the protected prostaglandin was subjected to acidic deprotection(cat. PPTS, acetone and water) and purification (chromatography on silica gel)to provide 15.8 g (60%) of misoprostol was identical.
2 method of synthesis
To a 300 ml dried flask under a nitrogen atmosphere was added 4.45 g ofcopper (I) iodide and 60 ml of anhydrous THF. The mixture was cooled to 0°C35 ml of 1.4 M methyllithium in diethyl ether was added dropwise and theresultant solution was stirred at 0°C for 30 min. 13.7 g of (E)-trimethyl-[[1-methyl-1-[3-(tributylstannyl)-2-propenyl]pentyl]oxy]silane in 5 ml of THF wasadded and then the mixture was stirred at 0°C for 30 min. Then an additional1.5 ml of 1.4 M methyllithium in diethyl ether was added and the mixture wasstirred for another 30 min. The reaction mixture was cooled to -78°C and 10 gof methyl 5-oxo-3-[(triethylsilyl)oxy]-1-cyclopentene-1-heptanoate in 10 ml ofTHF was added rapidly. After stirring the mixture for 5 min at -78°C, it wasquenched into 210 ml of basic aqueous ammonium chloride solution. Theresulting mixture was warmed to room temperature and stirred until a deepblue aqueous layer was obtained. Ethyl acetate was used for extraction. Thenthe combined organic layers were washed with water (10 ml), then with brine(25 ml) and subsequently dried over magnesium sulfate. After a filtration andconcentration under reduced pressure, an oil (21 g) was obtained. This oilcontaining the protected prostaglandin was subjected to acidic deprotection(cat. PPTS, acetone and water) and purification (chromatography on silica gel)to provide 4.2 g (40%) misoprostol.

brand name

Cytotec (Searle);Cyprostol;Oxaprost;Prostalgin.

Therapeutic Function

Antiulcer

General Description

Misoprostol, (±)-methyl 11α, 16-dihydroxy-16-methyl-9-oxoprost-13E-en-1-oate, is a semisyntheticderivative of PGE1 that derives some pharmacologicalselectivity as well as enhanced biostability from its16-methyl, 16-hydroxy substitutions. A mixture of misoprostoldiastereomers are present in the commercial product,but most of the activity is associated with the 11r, 16Sisomer. Misoprostol exhibits both antisecretory andcytoprotectant effects characteristic of the naturalprostaglandins and has a therapeutically acceptable biodisposition profile. Although the antisecretory effects of misoprostolare thought to be related to its agonistic actions atparietal cell prostaglandin receptors, its cytoprotective actionsare proposed to be related to increases in GI mucusand bicarbonate secretion, increases in mucosal blood flow,and/or prevention of back diffusion of acid into the gastricmucosa.
Misoprostol is rapidly absorbed following oral administrationand undergoes rapid deesterification to the pharmacologicallyactive free acid with a terminal half-life of 20 to40 minutes. Misoprostol is commonly used to preventNSAID-induced gastric ulcers in patients at high risk ofcomplications from a gastric ulcer, such as elderly patientsand patients with a history of ulcer. Misoprostol has alsobeen used in treating duodenal ulcers unresponsive to histamineH2-antagonists; the drug does not prevent duodenal ulcers,however, in patients taking NSAIDS. Misoprostol cancause miscarriage, often associated with potentially dangerousbleeding.

General Description

Misoprostol, (16-(R,S)-methyl-16-hydroxy)-PGE1, methyl ester (Cytotec), is a modified prostaglandinanalog that shows potent gastric antisecretory and gastroprotectiveeffects when administered orally. Misoprostol isadministered orally in tablet form in a dose of 100 to 200 μg4 times a day to prevent gastric ulceration in susceptibleindividuals who are taking NSAIDs. Misoprostol is combinedwith the NSAID diclofenac (Voltaren) in an analgesic product(Arthrotec by Pharmacia), which is potentially safe for longtermantiarthritic therapy. This prostaglandin derivative absolutelyshould be avoided by pregnant women because of itspotential to induce abortion. In fact, the combined use of intramuscularmethotrexate and intravaginal misoprostol has beenclaimed to be a safe and effective, noninvasive method for thetermination of early pregnancy.

Biological Activity

Cytoprotective prostaglandin E 1 analog that displays agonist activity at EP receptors. K i values are 120, 250, 67 and 67 nM at cloned mouse EP 1 , EP 2 , EP 3 and EP 4 receptors respectively. Prevents NSAID-induced gastric ulceration.

Pharmacology

Misoprostol is absorbed rapidly after oral administration and is hydrolyzed to the active compound. It is metabolized by the liver and excreted mainly in the urine. Adverse effects include crampy abdominal pain, dose-related diarrhea, and uterine contractions. The last-named effect has led to its use in the control of postpartum bleeding.

Veterinary Drugs and Treatments

Misoprostol may be useful as primary or adjunctive therapy in treating or preventing gastric ulceration, especially when caused or aggravated by non-steroidal antiinflammatory drugs (NSAIDs). Misoprostol is most useful to prevent GI ulceration or GI adverse effects (anorexia, vomiting) associated with NSAID therapy. While it can be used for treating gastric ulcers, other drugs are probably just as effective and less expensive. It does not appear to be very effective in reducing gastric ulceration secondary to high dose corticosteroid therapy Misoprostol may be efficacious in reducing or reversing cyclosporine- induced nephrotoxicity. More data is needed to confirm this effect.
One study demonstrated that misoprostol can reduce the clinical signs associated with atopy somewhat in dogs.
Misoprostol’s effects on uterine contractibility and cervical softening/ opening make it effective as an adjunctive treatment in pregnancy termination.

MisoprostolSupplier

Wuhan Xinru Chemical Co., Ltd. Gold
Tel
Email
2957608426@qq.com
J & K SCIENTIFIC LTD.
Tel
010-82848833- ;010-82848833-
Email
jkinfo@jkchemical.com;market6@jkchemical.com
Chemvon Biotechnology Co., Ltd
Tel
021-50790412-
Email
info@chemvon.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801
Email
3bsc@sina.com
Chembest Research Laboratories Limited
Tel
021-20908456-
Email
sales@BioChemBest.com